Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning

https://www.facingourrisk.org/research-clinical-trials/study/378/study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery

Study Contact Information:

Please contact:

Name: Revolution Medicines Study Director
Phone Number: 1-844-2-REVMED
Email: [email protected]

About the Study

This study is testing whether taking daraxonrasib, a new oral cancer medicine, after surgery and standard chemotherapy can help people with pancreatic cancer stay cancer-free for longer.

People in this study have already had their pancreatic tumor surgically removed and have completed chemotherapy before enrolling. The main goal is to see whether daraxonrasib can delay the return of cancer compared with standard care, which is watchful waiting without additional treatment.

What the Study Involves

People will be randomly assigned to one of two groups:

Group 1 Daraxonrasib group: Take daraxonrasib pills on a regular schedule determined by the study team.
Group 2 Standard care observation group: Continue regular follow-up visits with doctors without taking daraxonrasib.

All participants will have regular medical visits, scans, and tests over several years to check for cancer recurrence and monitor health. Researchers will compare how long people remain free of cancer in both groups.

This Study is Open To:

Adults (age 18 and older) who:

Had pancreatic cancer that was successfully removed by surgery.
Completed neoadjuvant and/or adjuvant chemotherapy before joining the study.
Have no current evidence that the cancer has come back or spread.
Have a documented RAS mutation in their tumor.
Are able to take medicine by mouth and meet certain health criteria (like organ function)

See full inclusion list here.

This Study is Not Open To:

People who:

Already received direct RAS-targeted therapy before this study.
Have health conditions that make it hard to take or absorb the study medicine.
Had major surgery within 28 days before joining.

See full exclusion list here.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.